Clinical Scorecard: Breye Raises €67.5M for Oral DR Therapy
At a Glance
| Category | Detail |
|---|---|
| Condition | Non-Proliferative Diabetic Retinopathy (NPDR) |
| Key Mechanisms | Danegaptide stabilizes retinal vasculature and protects against capillary breakdown and vascular leakage associated with chronic hyperglycemia. |
| Target Population | Patients with non-proliferative diabetic retinopathy. |
| Care Setting | Clinical trial setting for early-stage diabetic retinopathy treatment. |
Key Highlights
- Breye Therapeutics raised €67.5 million for danegaptide development.
- Danegaptide is an oral small molecule aimed at treating NPDR.
- The Phase II clinical trial is planned for 2027.
- The therapy showed early signs of clinical activity in a Phase Ib study.
- Danegaptide represents a potentially non-invasive treatment option.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with non-proliferative diabetic retinopathy.
Danegaptide may be used earlier in the disease course and alongside existing therapies.
Clinical Best Practices
- Consider oral therapies for NPDR to improve patient compliance.
- Monitor retinal imaging for signs of vascular leakage.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
